hat
Ibrutinib te kreye pa syantis nan Celera Genomics kòm yon konpoze zouti pou etidye BTK fonksyon, Lè sa a, devlope pa Pharmacyclics jiska Faz II, Lè sa a, patenarya ak Johnson & Johnson. Pharmacyclics te rann pa AbbVie nan mwa me 2015, ak Abbvie projetée lavant mondyal nan $ 1 milya dola nan 2016 ak $ 5 milya dola nan 2020, Tags cho: Diflorasone .
eng
Ibrutinib was created by scientists at Celera Genomics as a tool compound for studying BTK function, then developed by Pharmacyclics up to Phase II, then partnered with Johnson & Johnson. Pharmacyclics was acquired by AbbVie in May 2015, and Abbvie projected global sales of US$1 billion in 2016 and $5 billion in 2020,Hot tags: Diflorasone .